D-0065-2023 Class II Terminated
FDA drug recall D-0065-2023 was initiated by Nephron Sterile Compounding Center LLC on Nov 10, 2022 and is designated Class II. Reason for recall: CGMP Deviations: Potential for cross contamination due to product carry over. The recall status is terminated (terminated Sep 24, 2024). Affected quantity: 56,220 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2022
- Initiation Date
- Nov 10, 2022
- Termination Date
- Sep 24, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 56,220 vials
Product description
PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.
Reason for recall
CGMP Deviations: Potential for cross contamination due to product carry over.
Distribution pattern
Nationwide in the USA
Code information
Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0065-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026